search
Back to results

Supporting the Health of Adults Undergoing Orthopedic Surgery During the Recovery Period (SHARP)

Primary Purpose

Delirium

Status
Completed
Phase
Phase 2
Locations
United States
Study Type
Interventional
Intervention
donepezil
Placebo
Sponsored by
Beth Israel Deaconess Medical Center
About
Eligibility
Locations
Arms
Outcomes
Full info

About this trial

This is an interventional prevention trial for Delirium focused on measuring Delirium, Postoperative confusion, Hip fracture, Long bone fracture

Eligibility Criteria

70 Years - undefined (Older Adult)All SexesDoes not accept healthy volunteers

Inclusion Criteria:

  • hip or other long bone fracture undergoing operative repair
  • age of 70 years or older
  • the ability to communicate effectively in English (including adequate hearing)
  • residence within a 50 mile radius of the BIDMC
  • life expectancy 6 months or greater
  • not currently on cholinesterase inhibitor therapy
  • not with known hypersensitivity to cholinesterase inhibitors
  • not a previous study participant or refusal

Exclusion Criteria:

  • patients with sick sinus syndrome or greater than 1st degree AV block without a pacemaker
  • patients with a pathologic fracture due to metastatic cancer
  • patients with advanced dementia or total functional dependence.

Sites / Locations

  • Beth Israel Deaconess Medical Center

Arms of the Study

Arm 1

Arm 2

Arm Type

Active Comparator

Placebo Comparator

Arm Label

1

2

Arm Description

Outcomes

Primary Outcome Measures

Percentage of Participants With Delirium Using the CAM Over Time
Confusion Assessment Method (CAM)-Measure of the presence or absence of delirium. Requires 1) acute change with fluctuating course, 2) inattention, and either 3) disorganized thinking or 4) altered level of consciousness.

Secondary Outcome Measures

Change From Baseline and MDAS Scores Over Time
Measures severity of 10 delirium symptoms items (0 not present, 1 mild, 2 moderate, 3 severe) yielding a total score of 0 to 30, with 30 most severe.

Full Information

First Posted
December 21, 2007
Last Updated
August 21, 2014
Sponsor
Beth Israel Deaconess Medical Center
Collaborators
National Institute on Aging (NIA)
search

1. Study Identification

Unique Protocol Identification Number
NCT00586196
Brief Title
Supporting the Health of Adults Undergoing Orthopedic Surgery During the Recovery Period
Acronym
SHARP
Official Title
Supporting the Health of Adults Undergoing Orthopedic Surgery During the Recovery Period
Study Type
Interventional

2. Study Status

Record Verification Date
August 2014
Overall Recruitment Status
Completed
Study Start Date
January 2007 (undefined)
Primary Completion Date
February 2013 (Actual)
Study Completion Date
February 2013 (Actual)

3. Sponsor/Collaborators

Responsible Party, by Official Title
Principal Investigator
Name of the Sponsor
Beth Israel Deaconess Medical Center
Collaborators
National Institute on Aging (NIA)

4. Oversight

Data Monitoring Committee
Yes

5. Study Description

Brief Summary
Delirium (acute confusion) is a highly prevalent condition among hospitalized elders with substantial morbidity within the hospital and beyond. Particular patient populations are at high risk for poor outcomes after an episode of delirium. Patients with hip and other long bone fractures are at increased risk of developing delirium (acute confusion) which impedes functional recovery. This is a pilot study to test the tolerability and efficacy of donepezil, a cholinesterase inhibitor medication used commonly in persons with dementia, for the prevention of new or worsening delirium in aged hip and other long-bone fracture patients. Additional purposes involve gathering a small amount of patients' serum to better understand the pathophysiology of delirium in this population. The purposes of this pilot study are to determine: 1) the safety and tolerability a cholinesterase inhibitor medication) in aged hip and long bone fracture patients, 2) To obtain estimates of subject accrual and preliminary estimates of effect size on the development of new delirium symptoms to allow for planning of a larger, definitive trial, 3) To better understand the underlying causes of delirium by examining whether a measure of blood anticholinergic activity relates to the incidence and persistence of delirium symptoms, and 4) To explore the interaction between anticholinergic activity, donepezil therapy, and delirium symptoms.

6. Conditions and Keywords

Primary Disease or Condition Being Studied in the Trial, or the Focus of the Study
Delirium
Keywords
Delirium, Postoperative confusion, Hip fracture, Long bone fracture

7. Study Design

Primary Purpose
Prevention
Study Phase
Phase 2
Interventional Study Model
Parallel Assignment
Masking
ParticipantInvestigator
Allocation
Randomized
Enrollment
16 (Actual)

8. Arms, Groups, and Interventions

Arm Title
1
Arm Type
Active Comparator
Arm Title
2
Arm Type
Placebo Comparator
Intervention Type
Drug
Intervention Name(s)
donepezil
Other Intervention Name(s)
Aricept
Intervention Description
5 mg each day for 30 days
Intervention Type
Drug
Intervention Name(s)
Placebo
Intervention Description
Encapsulated cornstarch One capsule daily for 30 days
Primary Outcome Measure Information:
Title
Percentage of Participants With Delirium Using the CAM Over Time
Description
Confusion Assessment Method (CAM)-Measure of the presence or absence of delirium. Requires 1) acute change with fluctuating course, 2) inattention, and either 3) disorganized thinking or 4) altered level of consciousness.
Time Frame
Baseline, hospital interviews, weeks 2, 4 and 6
Secondary Outcome Measure Information:
Title
Change From Baseline and MDAS Scores Over Time
Description
Measures severity of 10 delirium symptoms items (0 not present, 1 mild, 2 moderate, 3 severe) yielding a total score of 0 to 30, with 30 most severe.
Time Frame
Baseline, hospital discharge, weeks 2, 4 and 6

10. Eligibility

Sex
All
Minimum Age & Unit of Time
70 Years
Accepts Healthy Volunteers
No
Eligibility Criteria
Inclusion Criteria: hip or other long bone fracture undergoing operative repair age of 70 years or older the ability to communicate effectively in English (including adequate hearing) residence within a 50 mile radius of the BIDMC life expectancy 6 months or greater not currently on cholinesterase inhibitor therapy not with known hypersensitivity to cholinesterase inhibitors not a previous study participant or refusal Exclusion Criteria: patients with sick sinus syndrome or greater than 1st degree AV block without a pacemaker patients with a pathologic fracture due to metastatic cancer patients with advanced dementia or total functional dependence.
Overall Study Officials:
First Name & Middle Initial & Last Name & Degree
Edward R Marcantonio, MD
Organizational Affiliation
Beth Israel Deaconess Medical Center
Official's Role
Principal Investigator
Facility Information:
Facility Name
Beth Israel Deaconess Medical Center
City
Boston
State/Province
Massachusetts
ZIP/Postal Code
02215
Country
United States

12. IPD Sharing Statement

Citations:
PubMed Identifier
22091574
Citation
Marcantonio ER, Palihnich K, Appleton P, Davis RB. Pilot randomized trial of donepezil hydrochloride for delirium after hip fracture. J Am Geriatr Soc. 2011 Nov;59 Suppl 2(Suppl 2):S282-8. doi: 10.1111/j.1532-5415.2011.03691.x.
Results Reference
result

Learn more about this trial

Supporting the Health of Adults Undergoing Orthopedic Surgery During the Recovery Period

We'll reach out to this number within 24 hrs